We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
International Biotechnology Trust Plc | LSE:IBT | London | Ordinary Share | GB0004559349 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 618.00 | 606.00 | 624.00 | - | 9,368 | 09:34:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | 12.06M | 6.81M | 0.1733 | 35.66 | 242.99M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/9/2006 14:31 | see IBT is starting an upward move presumably on the news of the use of genetically modified imune cells to fight skin cancer. | rogerl | |
05/5/2006 22:24 | No mention of IBT on Mike Walters - different Investment trust entirely! | anakin54321 | |
05/5/2006 22:08 | Without sounding to cheeky,i take it Michael Walters has just posted something on IBT.Does anybody know what it says?Thanks | 21up | |
03/5/2006 11:22 | thanks fickena,hadnt shown on watchlist. | j4ckthehat | |
03/5/2006 11:16 | Material Change to NAV RNS Number:3411C Intl. Biotechnology Trust PLC 03 May 2006 3 May 2006 MATERIAL CHANGE IN NET ASSET VALUE The Board of International Biotechnology Trust plc (the "Company") notes that due to two events within the portfolio, one of which is currently bound by confidentiality, the net asset value ("NAV") of the Company has, on a net basis, materially increased. The events, had they been incorporated into the last released NAV of 25 April 2006, would have increased the NAV per share by 11.64p, or, 8.18%. One of the events is the write down of Trine Pharmaceuticals from #1.3m to zero as a result of its uncertain financing position. Further comment on the other confidentiality-boun available. | fickena | |
03/5/2006 10:57 | a nice jump this morning? | j4ckthehat | |
10/3/2006 15:54 | Bought in today for long term, my reason is that Biotech in general has had a poor 3 years but it seems various breakthroughs in treatments of alkzeimers, parkinsons, and various cancers to say nothing of future possibilities to regenerate failing body parts will send the whole industry northwards in a most satifying way. | rogerl | |
08/2/2006 18:38 | Creeping up | 21up | |
30/1/2006 13:27 | Wait till August in my view. They're showing signs of multi year break out. I'm in at 119.I'm biased though, this was one of my best trade of all time, bought at.44 in Decembewr 1998, sold at 3.4 Feb 2000. Spread at this time is very tight for this stock, a goos sign in my view. | kingfast | |
20/12/2005 22:05 | Need a bit of help here.Has anybody any views on these shares?The daughter's getting married next year(August).Should i sell now or waite till August? | 21up | |
28/11/2005 23:14 | unwelcome news for the board... The Company was notified on 22 November 2005 that as at 9 November 2005, QVT Fund LP held a beneficial interest, through CrestCo Limited, in 7,217,000 ordinary shares of 25p each in the Company, being 15.17% of the 47,565,467 shares in issue. | rambutan2 | |
18/11/2005 11:20 | PS Collecting anything I find to do with IBT here: | fickena | |
18/11/2005 11:19 | AGM this morning. Don't suppose anyone has a link to the webcast? | fickena | |
18/11/2005 11:17 | blimey - lonely on here! seems to be a lot of +ve vibes for future of biotechs now with increasing gov encouragement and aid. nav 122p share price 108 so c12% disc lots of bio sp's rising so if the disc falls as well could be a good number used to hold years ago now back in & adding steadily in isa | gurp | |
21/6/2005 17:02 | yes, am sure it was. | rambutan2 | |
21/6/2005 16:09 | I can't see any RNS giving details of whether the proposals were accepted or not. Any news R2? | mart | |
01/4/2005 15:39 | The Bioscience Investment Trust plc Reconstruction proposals The Board of The Bioscience Investment Trust plc (the 'Company') announces that it has today posted a circular to shareholders detailing proposals for the reconstruction of the Company. Introduction The Board announced on 21 December 2004 that as a consequence of discussions with the Company's largest Shareholders it intended to put forward proposals to Shareholders for the future of the Company. The Directors have considered how best to satisfy the wishes of the Company's largest Shareholders to be able to realise the value of their shareholdings at close to net asset value while at the same time treating all Shareholders in an equal manner. The Directors are, therefore, putting forward for Shareholder approval proposals for the liquidation of the Company that will allow Shareholders to elect to rollover their investment into the Schroder Medical Discovery Fund and/or for cash and that will also involve all Shareholders retaining a pro rata interest in the Company's Unquoted Portfolio that will continue to be managed while the Company is in liquidation. The Board is convening an Extraordinary General Meeting to be held on 25 April 2005 for the purpose of obtaining approval for the Scheme, the detail of which is explained in the circular to shareholders. In the event that the Scheme is approved, a resolution for the winding up of the Company will be proposed at a Second Extraordinary General Meeting which is being convened for 13 May 2005. The Proposals... | rambutan2 | |
30/12/2004 12:14 | 24-Dec-04 To : The London Stock Exchange International Biotechnology Trust plc Sunesis Pharmaceuticals Inc. International Biotechnology Trust plc is pleased to note that Sunesis Pharmaceutical Inc. filed an S-1 registration statement with the SEC on 23 December 2004. The Board of International Biotechnology Trust plc announces that the top ten investments as at Tuesday 30 November 2004 were as follows: NAME % of Gross Assets Encysive Pharmaceuticals 6.37 Affibody 5.25 OSI Pharmaceuticals 4.73 Sunesis Pharmaceuticals 4.42 Eyetech Pharmaceuticals 4.26 AnorMed 3.60 Aderis Pharmaceuticals 3.31 Nektar Therapeutics 3.30 Inspire Pharmaceuticals 2.99 CancerVax 2.99 | rambutan2 | |
21/12/2004 12:30 | and tbs succumbs and offers shareholders a near nav exit. surely a good chance of the rump joining ibt?... Reconstruction Proposals The Board of 3i Bioscience announces that, as a consequence of discussions with the Company's largest shareholders, it intends to convene an Extraordinary General Meeting to consider proposals for a reconstruction. The proposals would involve offering shareholders the opportunity to realise their investment for a value as close to Net Asset Value as practicable, after allowing for the costs of realising the Company's investments and the illiquid nature of the portfolio of unquoted investments, which are currently valued at approximately £18 million. Subject to sufficient elections being made, the proposals will also involve offering shareholders who wish to maintain an exposure to the biotechnology sector the opportunity to invest in a vehicle managed by the current investment team. A circular to shareholders will be issued giving details of these proposals as soon as practicable. | rambutan2 | |
20/12/2004 22:16 | sorry pfizer | 21up | |
20/12/2004 18:02 | News about Eyetech on Bloomberg.Dual thing with Phizer | 21up | |
15/12/2004 17:08 | even more interesting (re 3i bio)... 15 December 2004 Substantial Share Interest Notification The Company was notified on 15 December 2004 that, following a purchase of 3,000,000 shares on 14 December 2004, Weiss Asset Management LLC and Weiss Capital LLC have an interest in 4,800,000 ordinary shares of 25p each, representing 10.73% of the 44,715,844 shares in issue. The shares have been purchased for 2 funds managed by Weiss Asset Management and Weiss Capital, Brookdale International Partners which holds 3,000,000 shares and Brookdale Global Opportunity Fund which holds 1,800,000 shares. add that to qvts stake and hmmm. | rambutan2 | |
06/12/2004 15:11 | im going to use this to post relevant stuff in 3i bio as well. qvt fund have been buying up shares for a few months now. note the signatory name - hes a legend... Date of acquisition: 3 December 2004 Acquisition in: 3i Bioscience Investment Trust PLC (1) Class of voting shares Number of shares/rights over If rights or shares (eg ordinary shares) shares acquired acquired, as opposed to the shares themselves, specify Ordinary shares 2,500,000 shares nature of rights 0 rights (2) Resultant total holding of Resultant total holding of rights Total percentage voting shares (and % of total over shares (and % of total voting voting shares in issue) shares in issue) 12,438,450 shares (28.35%) 0 ( %) 28.35 ( %) (3) Party making disclosure: QVT Fund LP (4) (a) Name of person acquiring shares or rights over shares: QVT Fund LP and, if different, beneficial owner: (b) Names of any other persons acting by agreement or understanding: Signed, for and on behalf of the party named in (3) above: Lars Bader (Also print name of signatory): Lars Bader Telephone and extension number: +1 (212) 705-8800 | rambutan2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions